ZOLMITRIPTAN Drug Patent Profile
✉ Email this page to a colleague
When do Zolmitriptan patents expire, and what generic alternatives are available?
Zolmitriptan is a drug marketed by Padagis Israel, Alembic, Apotex Inc, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Rising, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Ani Pharms, Aurobindo Pharma, Invagen Pharms, Natco Pharma Usa, Orbion Pharms, Pld Acquisitions Llc, Somerset Theraps Llc, Sun Pharma Global, and Zydus Pharms. and is included in twenty-three NDAs.
The generic ingredient in ZOLMITRIPTAN is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zolmitriptan
A generic version of ZOLMITRIPTAN was approved as zolmitriptan by GLENMARK PHARMS LTD on May 14th, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOLMITRIPTAN?
- What are the global sales for ZOLMITRIPTAN?
- What is Average Wholesale Price for ZOLMITRIPTAN?
Summary for ZOLMITRIPTAN
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 23 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 99 |
| Clinical Trials: | 23 |
| Patent Applications: | 4,660 |
| Drug Prices: | Drug price information for ZOLMITRIPTAN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZOLMITRIPTAN |
| What excipients (inactive ingredients) are in ZOLMITRIPTAN? | ZOLMITRIPTAN excipients list |
| DailyMed Link: | ZOLMITRIPTAN at DailyMed |
Recent Clinical Trials for ZOLMITRIPTAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Food and Drug Administration (FDA) | Phase 1 |
| Parc de Salut Mar | Phase 1 |
| William Stoops | Early Phase 1 |
Pharmacology for ZOLMITRIPTAN
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for ZOLMITRIPTAN
Paragraph IV (Patent) Challenges for ZOLMITRIPTAN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ZOMIG | Nasal Spray | zolmitriptan | 2.5 mg/spray | 021450 | 1 | 2016-06-09 |
| ZOMIG | Nasal Spray | zolmitriptan | 5 mg/spray | 021450 | 1 | 2013-11-14 |
US Patents and Regulatory Information for ZOLMITRIPTAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Somerset Theraps Llc | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 206973-001 | Jun 30, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Jubilant Generics | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 202279-002 | Nov 20, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 203019-001 | Jul 11, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Glenmark Pharms Ltd | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 201779-002 | May 14, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Macleods Pharms Ltd | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 203772-001 | Sep 30, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Invagen Pharms | ZOLMITRIPTAN | zolmitriptan | TABLET;ORAL | 204284-001 | Apr 9, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Israel | ZOLMITRIPTAN | zolmitriptan | SPRAY;NASAL | 212469-001 | Sep 30, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
